TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in signs of vaginal and vulvar dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: New brain infarction detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global Pittsburgh Sleep Quality Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Efficacy of Study Treatment Using Medicis Midface Volume Score (MMVS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Feasibility
Endpoint domain: Resource use
Primary endpoint: Number of eligible patients recruited per site per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of 1 or more increase in NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of grade 3 or 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Receiving pRBC Transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dyspnea during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Polysomnographic variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Non-anemic Patients With Iron Deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in anthropometric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammatory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy in sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic accuracy in sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients alive and dialysis-independent at 100 days
Endpoint domain: Mortality/survival
Primary endpoint: Emergency Department - Treat and Release (EDTR) Rate at 30-days
Endpoint domain: Mortality/survival
Primary endpoint: Symptomatic PE/DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tumor Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Surgical recovery score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Health-related quality of life (SF-36 MCS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 100% resolution of primary conjunctival-corneal intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Volume of total tooth and resorbed area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of widest mesio-distal length, bucco-lingual length and corono-apical length of the resorbed lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear measurements for thinnest dentin and resorbed area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: naming accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Concentration of individual serum biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With 50 Percent Or Greater Reduction in the MADRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in serum uric acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Assessment of Cancer Therapy-General (FACT-G) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daily Steps Change From Baseline to Month 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose of irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Health related quality of life: EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum dose of external beam irradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in mean FA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: low blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular safety parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histology and grade of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patients' responses to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OxiCable pulse rate measurement performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline arterial blood gases (ABG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of colonisation by Clostridium bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Local Control at 2 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Glucagon and Glucose concentrations in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in shoulder pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly Rates of Anti-VEGF Injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Skin pigmentation extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: University of Miami Parkinson's disease Hallucinations Questionnaire (UM-PDHQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Multi-Modality Unusual Sensory Experiences Questionnaire (MUSEQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thioguanine Levels in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Methylmercaptopurine Levels in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of current surgery in restoring nasal function based on volumetric airflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of current surgery in restoring nasal function based on nasal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of current surgery in restoring nasal function based on nasal heat flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Margin Reflex distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Blood Plasma Phenylalanine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-treatment depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in markers of macrophage abundance in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time of placement for a perineural catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survival from any VA recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Glucagon like peptide (GLP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peptide YY (PYY)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Growth Differentiation Factor-15 (GDF 15)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Primary and secondary hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in ZAN-BPD total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life using semi-structured interview
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life using 36-Item Short Form Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life using State-Trait Anxiety Inventory (STAY) A+B scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life using Beck Depressive Inventory (BDI) -13
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient compliance defined as therapy break-offs
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 25 Hydroxy Vitamin D (25OHD) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with a dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Percentage of Breast Epithelial Cells Expressing Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change in Disease Activity Score 28 (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of lung vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of blood oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Forced Vital Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Successful Fusion Status at 1 Year Post-Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oswestry Disability Index (ODI) from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Visual Analog Scale (VAS) Leg and Back Pain Scores from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Area under the plasma concentration versus time curve for all drug analytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in QT intervals from baseline (single dose DP)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in QT intervals from baseline (3-dose DP regimens)
Endpoint domain: Adverse events/effects
Primary endpoint: Cognition failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Participants That Select to Complete an Advance Directive
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Geometric Mean Concentrations (GMCs) of Anti-Pneumococcal Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absorption, distribution, metabolism and excretion of AZD7325
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calf Muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 12 month admission free survival
Endpoint domain: Mortality/survival
Primary endpoint: Mechanical Lens Fit Acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic Lens Fit Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lens Does Not Exhibit Hula Hoop Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary caffeine and related metabolites excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Achieving Remission (DAS 28 < 2.6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Year 1 Participants Having an Annualized Modified Total Sharp Score (mTSS < 0.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction/Elimination of snoring behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Choroidal Neovascularization (CNV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Quality of Life as measured by QoL-AD and DQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rectus femoris cross-sectional area (RFCSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rectus femoris linear depth (RF LD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of NiPGT-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of NiPGT-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of osteoradionecrosis (ORN)
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial Endothelial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Concentration of Norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of Epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Analgesic effect of gabapentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of indium-111 BU-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Cisplatin with Radiation
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in particulate matter 2.5 (PM2.5) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in Preoperative P-PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of mucositis grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in somnolence
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in perceived competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Apnea-hypoanea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Air Leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evolution of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of PTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTV coverage by 95% isodose line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children having ferritin >20 µg/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of adequate control of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of adequate control of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of adequate control of blood lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cure of Trichuris trichiura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in Trichuris trichiura eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SPECT- and MRI-measured flow values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back pain intensity - total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back pain-related functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants who receive a voucher
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety and tolerability based on drug-related dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of forefoot pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of colorectal cancer recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Successful Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant laboratory assessment abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant Vital sign abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of lipids in the endometrial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful oxygenation and ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Contraception use - 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pregnancy - 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Contraception use - 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pregnancy - 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: hemodialysis access maturation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended dose of bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Attack Duration of Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ Failure
Endpoint domain: Mortality/survival
Primary endpoint: Dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision-making impact
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pre-term delivery
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of dissociative symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in galanin expression in mucosal nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in glycemic control (A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of Radiation-induced Nausea and Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pre eclampsia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Understanding of CRISPR Cas9
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes